Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130 · see citing works

Identification and characterization of a new member of the TNF family that induces apoptosis

Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C.-P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90057-8 · Cited by 2,900 · see citing works

A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.

Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., & Galibert, L. (1997) · Nature · doi:10.1038/36593 · Cited by 2,290 · see citing works

Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family

Pitti, R. M., Marsters, S. A., Ruppert, S., Donahue, C. J., Moore, A., & Ashkenazi, A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.22.12687 · Cited by 1,777 · see citing works

Crystal structure of the soluble human 55 kd TNF receptor-human TNFβ complex: Implications for TNF receptor activation

Banner, D. W., D'Arcy, A., Janes, W., Gentz, R., Schönfeld, H., Broger, C., Loetscher, H., & Lesslauer, W. (1993) · Cell · doi:10.1016/0092-8674(93)90132-a · Cited by 1,097 · see citing works

TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells

Wong, B. R., Rho, J., Arron, J. R., Robinson, E. A., Orlinick, J. R., Chao, M. V., Kalachikov, S. M., Cayani, E., Bartlett, F. S., Frankel, W. N., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.40.25190 · Cited by 1,042 · see citing works

Modulation of Osteoclast Differentiation

Suda, T., Takahashi, N., & Martin, T. J. (1992) · Endocrine Reviews · doi:10.1210/edrv-13-1-66 · Cited by 996 · see citing works

Osteoclast-Like Cell Formation and its Regulation by Osteotropic Hormones in Mouse Bone Marrow Cultures*

Takahashi, N., Yamana, H., Yoshiki, S., Roodman, G. D., Mundy, G. R., Jones, S. J., BOYDE, A., & Suda, T. (1988) · Endocrinology · doi:10.1210/endo-122-4-1373 · Cited by 731 · see citing works

Signal Transduction by DR3, a Death Domain-Containing Receptor Related to TNFR-1 and CD95

Chinnaiyan, A. M., O’Rourke, K. M., Yu, G.-L., Lyons, R. H., Garg, M., Duan, D. R., Xing, L., Gentz, R., Ni, J., & Dixit, V. M. (1996) · Science · doi:10.1126/science.274.5289.990 · Cited by 653 · see citing works

Bone resorbing activity in supernatant fluid from cultured human peripheral blood leukocytes

Horton, J. E., Raisz, L. G., Simmons, H. A., Oppenheim, J. J., & Mergenhagen, S. E. (1972) · Science · doi:10.1126/science.177.4051.793 · Cited by 565 · see citing works

Effect of pH on Bone Resorption by Rat Osteoclastsin Vitro

Arnett, T. R., & Dempster, D. W. (1986) · Endocrinology · doi:10.1210/endo-119-1-119 · Cited by 349 · see citing works

Fundamental principles of in situ hybridization.

Wilcox, J. N. (1993) · Journal of Histochemistry & Cytochemistry · doi:10.1177/41.12.8245419 · Cited by 246 · see citing works

B61 is a ligand for the ECK receptor protein-tyrosine kinase

Bartley, T. D., Hunt, R. W., Welcher, A. A., et al. (1994) · Nature · doi:10.1038/368558a0 · Cited by 246 · see citing works

Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-Δ11b

Wilson, C., Payton, M. N., Elliott, G., Buaas, F. W., Cajulis, E. E., Grosshans, D. R., Ramos, L., Reese, D., Slamon, D. J., & Calzone, F. J. (1997) · Oncogene · doi:10.1038/sj.onc.1200924 · Cited by 193 · see citing works

ATAR, a Novel Tumor Necrosis Factor Receptor Family Member, Signals through TRAF2 and TRAF5

Hsu, H., Solovyev, I., Colombero, A. M., Elliott, R., Kelley, M. J., & Boyle, W. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.21.13471 · Cited by 180 · see citing works

Differentiation-inducing factor purified from conditioned medium of mitogen-treated spleen cell cultures stimulates bone resorption.

Abe, E., Tanaka, H., Ishimi, Y., et al. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.16.5958 · Cited by 126 · see citing works

Interleukin 4, interferon-gamma, and prostaglandin E impact the osteoclastic cell-forming potential of murine bone marrow macrophages

Lacey, D. L., Erdmann, J. M., Teitelbaum, S. L., Tan, H., Ohara, J., & Shioi, A. (1995) · Endocrinology · doi:10.1210/endo.136.6.7750457 · Cited by 87 · see citing works

Mapping the Domain(s) Critical for the Binding of Human Tumor Necrosis Factor-α to Its Two Receptors

Chen, P. C.-H., DuBois, G. C., & Chen, M.-J. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.6.2874 · Cited by 58 · see citing works

Osteoclast resorption — stimulating activity is associated with the osteoblast cell surface and/or the extracellular matrix

Fuller, K., Gallagher, A. C., & Chambers, T. J. (1991) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(05)81382-8 · Cited by 52 · see citing works

Isolation of a murine osteoclast colony-stimulating factor.

Lee, M. Y., Eyre, D. R., & Osborne, W. R. A. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.19.8500 · Cited by 41 · see citing works

Osteoclast recruiting activity in bone matrix

Hentunen, T. A., Cunningham, N. S., Vuolteenaho, O. J., et al. (1994) · Bone and Mineral · doi:10.1016/s0169-6009(08)80238-3 · Cited by 24 · see citing works

c-fos antisense DNA inhibits proliferation of osteoclast progenitors in osteoclast development but not macrophage differentiation in vitro

Udagawa, N. (1996) · Bone · doi:10.1016/8756-3282(96)00076-2 · Cited by 21 · see citing works

A novel cytokine with osteoclastopoietic activity

Yoneda, T., Kato, I., Bonewald, L. F., et al. (1993) · Journal of Periodontal Research · doi:10.1111/j.1600-0765.1993.tb02117.x · Cited by 9 · see citing works

Osteoclast differentiation and activation

Boyle, W. J., Simonet, W. S., & Lacey, D. L. (2003) · Nature · doi:10.1038/nature01658 · Cited by 6,670 · see citing works

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.

Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351 · see citing works

Signalling pathways of the TNF superfamily: a double-edged sword

Aggarwal, B. B. (2003) · Nature Reviews Immunology · doi:10.1038/nri1184 · Cited by 2,793 · see citing works

Induction and Activation of the Transcription Factor NFATc1 (NFAT2) Integrate RANKL Signaling in Terminal Differentiation of Osteoclasts

Takayanagi, H., Kim, S., Koga, T., Nishina, H., Isshiki, M., Yoshida, H., Saiura, A., Isobe, M., Yokochi, T., Inoue, J.-I., et al. (2002) · Developmental Cell · doi:10.1016/s1534-5807(02)00369-6 · Cited by 2,701 · see citing works

Leptin Inhibits Bone Formation through a Hypothalamic Relay

Ducy, P., Amling, M., Takeda, S., Priemel, M., Schilling, A. F., Beil, F. T., Shen, J., Vinson, C., Rueger, J. M., & Karsenty, G. (2000) · Cell · doi:10.1016/s0092-8674(00)81558-5 · Cited by 2,077 · see citing works

Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems

Takayanagi, H. (2007) · Nature Reviews Immunology · doi:10.1038/nri2062 · Cited by 1,878 · see citing works

Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand.

Kong, Y.-Y., Feige, U., Sarosi, I., Bolon, B., Tafuri, A., Morony, S., Capparelli, C., Li, J., Elliott, R., McCabe, S., et al. (1999) · Nature · doi:10.1038/46303 · Cited by 1,856 · see citing works

Mechanisms involved in the side effects of glucocorticoids

SCHACKE, H. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00297-8 · Cited by 1,847 · see citing works

Functions of RANKL/RANK/OPG in bone modeling and remodeling

Boyce, B. F., & Xing, L. (2008) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2008.03.018 · Cited by 1,844 · see citing works

Therapeutic Approaches to Bone Diseases

Rodan, G. A., & Martin, T. J. (2000) · Science · doi:10.1126/science.289.5484.1508 · Cited by 1,767 · see citing works

Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand.

Hsu, H., Lacey, D. L., Dunstan, C. R., Solovyev, I., Colombero, A., Timms, E., Tan, H.-L., Elliott, G., Kelley, M. J., Sarosi, I., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3540 · Cited by 1,636 · see citing works

Canonical wnt signaling in differentiated osteoblasts controls osteoclast differentiation.

Glass, D. A., Bialek, P., Ahn, J. D., Starbuck, M., Patel, M. S., Clevers, H., Taketo, M. M., Long, F., McMahon, A. P., Lang, R. A., et al. (2005) · Developmental Cell · doi:10.1016/j.devcel.2005.02.017 · Cited by 1,558 · see citing works

RANK is essential for osteoclast and lymph node development.

Dougall, W. C., Glaccum, M., Charrier, K., Rohrbach, K., Brasel, K., De Smedt, T., Daro, E., Smith, J., Tometsko, M. E., Maliszewski, C. R., et al. (1999) · Genes & Development · doi:10.1101/gad.13.18.2412 · Cited by 1,478 · see citing works

Inflammatory and immune pathways in the pathogenesis of periodontal disease

Cekici, A., Kantarci, A., Hasturk, H., & Van Dyke, T. E. (2014) · Periodontology 2000 · doi:10.1111/prd.12002 · Cited by 1,415 · see citing works

Minireview: The OPG/RANKL/RANK System

Khosla, S. (2001) · Endocrinology · doi:10.1210/endo.142.12.8536 · Cited by 1,515 · see citing works

Leptin regulation of bone resorption by the sympathetic nervous system and CART

Elefteriou, F., Ahn, J. D., Takeda, S., Starbuck, M., Yang, X., Liu, X., Kondo, H., Richards, W. G., Bannon, T. W., Noda, M., et al. (2005) · Nature · doi:10.1038/nature03398 · Cited by 1,311 · see citing works

Matrix-embedded cells control osteoclast formation

Xiong, J., Onal, M., Jilka, R. L., Weinstein, R. S., Manolagas, S. C., & O'Brien, C. A. (2011) · Nature Medicine · doi:10.1038/nm.2448 · Cited by 1,304 · see citing works

Disorders of Bone Remodeling

Feng, X., & McDonald, J. M. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130203 · Cited by 1,272 · see citing works

Denosumab in postmenopausal women with low bone mineral density.

McClung, M. R., Lewiecki, E. M., Cohen, S. B., Bolognese, M. A., Woodson, G. C., Moffett, A. H., Peacock, M., Miller, P. D., Lederman, S. N., Chesnut, C. H., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044459 · Cited by 1,228 · see citing works

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

Smith, M. R., Egerdie, B., Toriz, N. H., Feldman, R., Tammela, T. L. J., Saad, F., Heracek, J., Szwedowski, M., Ke, C., Kupic, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809003 · Cited by 1,140 · see citing works

RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis, and regulation of bone mass and calcium metabolism.

Li, J., Sarosi, I., Yan, X.-Q., Morony, S., Capparelli, C., Tan, H.-L., McCabe, S., Elliott, R., Scully, S., Van, G., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.4.1566 · Cited by 1,119 · see citing works

Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment

Schett, G., & Gravallese, E. (2012) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2012.153 · Cited by 947 · see citing works

The aging of the immune system

Weiskopf, D., Weinberger, B., & Grubeck-Loebenstein, B. (2009) · Transplant International · doi:10.1111/j.1432-2277.2009.00927.x · Cited by 908 · see citing works

Estrogens and androgens in skeletal physiology and pathophysiology

Almeida, M., Laurent, M. R., Dubois, V., Claessens, F., O'Brien, C. A., Bouillon, R., Vanderschueren, D., & Manolagas, S. C. (2017) · Physiological Reviews · doi:10.1152/physrev.00033.2015 · Cited by 860 · see citing works

Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease

Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824 · see citing works

TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis.

Pettit, A. R., Ji, H., von Stechow, D., Müller, R., Goldring, S. R., Choi, Y., Benoist, C., & Gravallese, E. M. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63016-7 · Cited by 807 · see citing works

Regulation of cancer cell migration and bone metastasis by RANKL.

Jones, D. H., Nakashima, T., Sanchez, O. H., Kozieradzki, I., Komarova, S. V., Sarosi, I., Morony, S., Rubin, E., Sarao, R., Hojilla, C. V., et al. (2006) · Nature · doi:10.1038/nature04524 · Cited by 796 · see citing works

Buried alive: How osteoblasts become osteocytes

Franz‐Odendaal, T. A., Hall, B. K., & Witten, P. E. (2006) · Developmental Dynamics · doi:10.1002/dvdy.20603 · Cited by 795 · see citing works

Stimulation of Osteoprotegerin Ligand and Inhibition of Osteoprotegerin Production by Glucocorticoids in Human Osteoblastic Lineage Cells: Potential Paracrine Mechanisms of Glucocorticoid-Induced Osteoporosis1

Hofbauer, L. C., Gori, F., Riggs, B. L., Lacey, D. L., Dunstan, C. R., Spelsberg, T. C., & Khosla, S. (1999) · Endocrinology · doi:10.1210/endo.140.10.7034 · Cited by 794 · see citing works

The osteoclast differentiation factor osteoprotegerin ligand is essential for mammary gland development.

Fata, J. E., Kong, Y.-Y., Li, J., Sasaki, T., Irie-Sasaki, J., Moorehead, R. A., Elliott, R., Scully, S., Voura, E. B., Lacey, D. L., et al. (2000) · Cell · doi:10.1016/s0092-8674(00)00103-3 · Cited by 756 · see citing works

RANK Is the Essential Signaling Receptor for Osteoclast Differentiation Factor in Osteoclastogenesis

Nakagawa, N., Kinosaki, M., Yamaguchi, K., Shima, N., Yasuda, H., Yano, K., Morinaga, T., & Higashio, K. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9788 · Cited by 746 · see citing works

OSTEOIMMUNOLOGY: Interplay Between the Immune System and Bone Metabolism

Walsh, M. C., Kim, N., Kadono, Y., Rho, J., Lee, S. Y., Lorenzo, J., & Choi, Y. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090646 · Cited by 724 · see citing works

Osteoclasts: What Do They Do and How Do They Do It?

Teitelbaum, S. L. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.060834 · Cited by 730 · see citing works

Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-α

Cenci, S., Weitzmann, M. N., Roggia, C., Namba, N., Novack, D., Woodring, J., & Pacifici, R. (2000) · Journal of Clinical Investigation · doi:10.1172/jci11066 · Cited by 705 · see citing works

The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.

Burgess, T. L., Qian, Y.-X., Kaufman, S., Ring, B. D., Van, G., Capparelli, C., Kelley, M., Hsu, H., Boyle, W. J., Dunstan, C. R., et al. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.145.3.527 · Cited by 689 · see citing works

Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor κB (RANK) receptors.

Arai, F., Miyamoto, T., Ohneda, O., Inada, T., Sudo, T., Brasel, K., Miyata, T., Anderson, D. M., & Suda, T. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.12.1741 · Cited by 693 · see citing works

Role of RANK ligand in mediating increased bone resorption in early postmenopausal women

Eghbali-Fatourechi, G., Khosla, S., Sanyal, A., Boyle, W. J., Lacey, D. L., & Riggs, B. L. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17215 · Cited by 825 · see citing works

The cell biology of bone metabolism

Datta, H. K., Ng, W. F., Walker, J. A., Tuck, S. P., & Varanasi, S. S. (2008) · Journal of Clinical Pathology · doi:10.1136/jcp.2007.048868 · Cited by 614 · see citing works

Biology of the RANKL–RANK–OPG System in Immunity, Bone, and Beyond

Walsh, M. C., & Choi, Y. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00511 · Cited by 599 · see citing works

Matrix Metalloproteinase 9 and Vascular Endothelial Growth Factor Are Essential for Osteoclast Recruitment into Developing Long Bones

Engsig, M. T., Chen, Q.-J., Vu, T. H., Pedersen, A.-C., Therkidsen, B., Lund, L. R., Henriksen, K., Lenhard, T., Foged, N. T., Werb, Z., et al. (2000) · The Journal of Cell Biology · doi:10.1083/jcb.151.4.879 · Cited by 596 · see citing works

Osteopetrosis: genetics, treatment and new insights into osteoclast function

Sobacchi, C., Schulz, A., Coxon, F. P., Villa, A., & Helfrich, M. H. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.137 · Cited by 580 · see citing works

Role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biology

Hofbauer, L. C., & Heufelder, A. E. (2001) · Journal of Molecular Medicine · doi:10.1007/s001090100226 · Cited by 586 · see citing works

Expression of osteoprotegerin, receptor activator of NF-κB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing.

Kon, T., Cho, T.-J., Aizawa, T., Yamazaki, M., Nooh, N., Graves, D., Gerstenfeld, L. C., & Einhorn, T. A. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.6.1004 · Cited by 552 · see citing works

Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis.

Min, H., Morony, S., Sarosi, I., Dunstan, C. R., Capparelli, C., Scully, S., Van, G., Kaufman, S., Kostenuik, P. J., Lacey, D. L., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.4.463 · Cited by 550 · see citing works

Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis

Maeda, K., Kobayashi, Y., Udagawa, N., Uehara, S., Ishihara, A., Mizoguchi, T., Kikuchi, Y., Takada, I., Kato, S., Kani, S., et al. (2012) · Nature Medicine · doi:10.1038/nm.2653 · Cited by 542 · see citing works

Role of Thyroid Hormones in Skeletal Development and Bone Maintenance

Bassett, J. H. D., & Williams, G. R. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1106 · Cited by 540 · see citing works

Breast Cancer Cells Interact with Osteoblasts to Support Osteoclast Formation1

Thomas, R. J., Guise, T. A., Yin, J. J., Elliott, J., Horwood, N. J., Martin, T. J., & Gillespie, M. T. (1999) · Endocrinology · doi:10.1210/endo.140.10.7037 · Cited by 536 · see citing works

Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression.

Pearse, R. N., Sordillo, E. M., Yaccoby, S., Wong, B. R., Liau, D. F., Colman, N., Michaeli, J., Epstein, J., & Choi, Y. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.201394498 · Cited by 518 · see citing works

Nitric oxide and bone

Van'T Hof, R. J., & Ralston, S. H. (2001) · Immunology · doi:10.1046/j.1365-2567.2001.01261.x · Cited by 518 · see citing works

Up-regulation of TNF-producing T cells in the bone marrow: A key mechanism by which estrogen deficiency induces bone loss <i>in vivo</i>

Roggia, C., Gao, Y., Cenci, S., Weitzmann, M. N., Toraldo, G., Isaia, G., & Pacifici, R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251534698 · Cited by 513 · see citing works

Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-jun repression.

Shevde, N. K., Bendixen, A. C., Dienger, K. M., & Pike, J. W. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.130200197 · Cited by 502 · see citing works

Developmental origin, functional maintenance and genetic rescue of osteoclasts

Jacome-Galarza, C. E., Percin, G. I., Muller, J. T., Mass, E., Lazarov, T., Eitler, J., Rauner, M., Yadav, V. K., Crozet, L., Bohm, M., et al. (2019) · Nature · doi:10.1038/s41586-019-1105-7 · Cited by 475 · see citing works

A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.

Body, J.-J., Facon, T., Coleman, R. E., Lipton, A., Geurs, F., Fan, M., Holloway, D., Peterson, M. C., & Bekker, P. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1933 · Cited by 490 · see citing works

The effect of a single dose of osteoprotegerin in postmenopausal women.

Bekker, P. J., Holloway, D., Nakanishi, A., Arrighi, M., Leese, P. T., & Dunstan, C. R. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.2.348 · Cited by 484 · see citing works

Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation.

Lee, S.-K., & Lorenzo, J. A. (1999) · Endocrinology · doi:10.1210/endo.140.8.6887 · Cited by 464 · see citing works

Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone.

Zhang, J., Dai, J., Qi, Y., Lin, D.-L., Smith, P., Strayhorn, C., Mizokami, A., Fu, Z., Westman, J., & Keller, E. T. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11685 · Cited by 452 · see citing works

Modeling the interactions between osteoblast and osteoclast activities in bone remodeling

Lemaire, V., Tobin, F. L., Greller, L. D., Cho, C. R., & Suva, L. J. (2004) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2004.03.023 · Cited by 452 · see citing works

Essential Role of p38 Mitogen-activated Protein Kinase in Cathepsin K Gene Expression during Osteoclastogenesis through Association of NFATc1 and PU.1

Matsumoto, M., Kogawa, M., Wada, S., Takayanagi, H., Tsujimoto, M., Katayama, S., Hisatake, K., & Nogi, Y. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408795200 · Cited by 436 · see citing works

The role of NFAT in osteoclast formation

TAKAYANAGI, H. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1402.071 · Cited by 442 · see citing works

Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation.

Ma, Y. L., Cain, R. L., Halladay, D. L., Yang, X., Zeng, Q., Miles, R. R., Chandrasekhar, S., Martin, T. J., & Onyia, J. E. (2001) · Endocrinology · doi:10.1210/endo.142.9.8356 · Cited by 428 · see citing works

RANK/RANKL: Regulators of Immune Responses and Bone Physiology

Leibbrandt, A., & Penninger, J. M. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1443.016 · Cited by 420 · see citing works

Osteoblast and osteocyte: Games without frontiers

Capulli, M., Paone, R., & Rucci, N. (2014) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2014.05.003 · Cited by 413 · see citing works

Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment

Giuliani, N., Bataille, R., Mancini, C., Lazzaretti, M., & Barillé, S. (2001) · Blood · doi:10.1182/blood.v98.13.3527 · Cited by 415 · see citing works

Mechanistic insight into osteoclast differentiation in osteoimmunology

Takayanagi, H. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-004-0612-6 · Cited by 413 · see citing works

Receptor Activator of NF-κB and Osteoprotegerin Expression by Human Microvascular Endothelial Cells, Regulation by Inflammatory Cytokines, and Role in Human Osteoclastogenesis

Collin-Osdoby, P., Rothe, L., Anderson, F., Nelson, M., Maloney, W., & Osdoby, P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010153200 · Cited by 398 · see citing works

Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo.

Lacey, D. L., Tan, H. L., Lu, J., Kaufman, S., Van, G., Qiu, W., Rattan, A., Scully, S., Fletcher, F., Juan, T., et al. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64556-7 · Cited by 391 · see citing works

Glucocorticoids suppress bone formation via the osteoclast.

Kim, H.-J. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28084 · Cited by 384 · see citing works

Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases.

Lipton, A., Steger, G. G., Figueroa, J., Alvarado, C., Solal-Celigny, P., Body, J.-J., de Boer, R., Berardi, R., Gascon, P., Tonkin, K. S., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.8604 · Cited by 389 · see citing works

A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases

Body, J.-J., Greipp, P., Coleman, R. E., Facon, T., Geurs, F., Fermand, J.-P., Harousseau, J.-L., Lipton, A., Mariette, X., Williams, C. D., et al. (2003) · Cancer · doi:10.1002/cncr.11138 · Cited by 383 · see citing works

Large Scale Gene Expression Analysis of Osteoclastogenesisin Vitro and Elucidation of NFAT2 as a Key Regulator

Ishida, N., Hayashi, K., Hoshijima, M., Ogawa, T., Koga, S., Miyatake, Y., Kumegawa, M., Kimura, T., & Takeya, T. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205063200 · Cited by 377 · see citing works

Immune modulation by mesenchymal stem cells

Rasmusson, I. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2006.03.019 · Cited by 374 · see citing works

Mechanisms of sex steroid effects on bone

Syed, F., & Khosla, S. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.11.097 · Cited by 380 · see citing works

Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D.

Price, P. A., June, H. H., Buckley, J. R., & Williamson, M. K. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/hq1001.097102 · Cited by 376 · see citing works

Pathophysiology of Age-Related Bone Loss and Osteoporosis

Khosla, S., & Riggs, B. L. (2005) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2005.07.009 · Cited by 376 · see citing works

Osteoprotegerin Reduces Osteoclast Numbers and Prevents Bone Erosion in Collagen-Induced Arthritis

Romas, E., Sims, N. A., Hards, D. K., Lindsay, M., Quinn, J. W. M., Ryan, P. F. J., Dunstan, C. R., Martin, T. J., & Gillespie, M. T. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64417-3 · Cited by 368 · see citing works

Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis.

Yano, K., Tsuda, E., Washida, N., Kobayashi, F., Goto, M., Harada, A., Ikeda, K., Higashio, K., & Yamada, Y. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.4.518 · Cited by 363 · see citing works

M-CSF, TNFα and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase

Glantschnig, H., Fisher, J. E., Wesolowski, G., Rodan, G. A., & Reszka, A. A. (2003) · Cell Death &amp; Differentiation · doi:10.1038/sj.cdd.4401285 · Cited by 350 · see citing works

Matrix metalloproteinases (MMP) and cathepsin K contribute differently to osteoclastic activities

Delaissé, J., Andersen, T. L., Engsig, M. T., Henriksen, K., Troen, T., & Blavier, L. (2003) · Microscopy Research and Technique · doi:10.1002/jemt.10374 · Cited by 341 · see citing works

The RANKL/RANK/OPG pathway

Boyce, B. F., & Xing, L. (2007) · Current Osteoporosis Reports · doi:10.1007/s11914-007-0024-y · Cited by 339 · see citing works

Paget disease of bone.

Roodman, G. D., & Windle, J. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24281 · Cited by 340 · see citing works

Osteocytes, not Osteoblasts or Lining Cells, are the Main Source of the RANKL Required for Osteoclast Formation in Remodeling Bone

Xiong, J., Piemontese, M., Onal, M., Campbell, J., Goellner, J. J., Dusevich, V., Bonewald, L., Manolagas, S. C., & O’Brien, C. A. (2015) · PLOS ONE · doi:10.1371/journal.pone.0138189 · Cited by 323 · see citing works

Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD

Lewiecki, E. M., Miller, P. D., McClung, M. R., Cohen, S. B., Bolognese, M. A., Liu, Y., Wang, A., Siddhanti, S., & Fitzpatrick, L. A. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070809 · Cited by 319 · see citing works

RANKL/RANK/OPG Pathway: A Mechanism Involved in Exercise-Induced Bone Remodeling

Tobeiha, M., Moghadasian, M. H., Amin, N., & Jafarnejad, S. (2020) · BioMed Research International · doi:10.1155/2020/6910312 · Cited by 309 · see citing works

OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40.

Yun, T. J., Chaudhary, P. M., Shu, G. L., Frazer, J. K., Ewings, M. K., Schwartz, S. M., Pascual, V., Hood, L. E., & Clark3, E. A. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.11.6113 · Cited by 307 · see citing works

Osteoprotegerin Inactivation Accelerates Advanced Atherosclerotic Lesion Progression and Calcification in Older ApoE ^−/− Mice

Bennett, B. J., Scatena, M., Kirk, E. A., Rattazzi, M., Varon, R. M., Averill, M., Schwartz, S. M., Giachelli, C. M., & Rosenfeld, M. E. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000236428.91125.e6 · Cited by 304 · see citing works

Myeloma interacts with the bone marrow microenvironment 
to induce osteoclastogenesis and is dependent on osteoclast activity

Yaccoby, S., Pearse, R. N., Johnson, C. L., Barlogie, B., Choi, Y., & Epstein, J. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03257.x · Cited by 305 · see citing works

Transforming Growth Factor-β Stimulates the Production of Osteoprotegerin/Osteoclastogenesis Inhibitory Factor by Bone Marrow Stromal Cells

Takai, H., Kanematsu, M., Yano, K., Tsuda, E., Higashio, K., Ikeda, K., Watanabe, K., & Yamada, Y. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.42.27091 · Cited by 299 · see citing works

Effects of inflammatory and anti‐inflammatory cytokines on the bone

Schett, G. (2011) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2011.02545.x · Cited by 292 · see citing works

Gut, inflammation and osteoporosis: Basic and clinical concepts

Tilg, H., Moschen, A. R., Kaser, A., Pines, A., & Dotan, I. (2008) · Gut · doi:10.1136/gut.2006.117382 · Cited by 292 · see citing works

Receptor activator of nuclear factor κB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis.

Grimaud, E., Soubigou, L., Couillaud, S., Coipeau, P., Moreau, A., Passuti, N., Gouin, F., Redini, F., & Heymann, D. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63560-2 · Cited by 282 · see citing works

Molecular and cellular biology of alveolar bone

SODEK, J., & MCKEE, M. D. (2000) · Periodontology 2000 · doi:10.1034/j.1600-0757.2000.2240106.x · Cited by 283 · see citing works

Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength.

KOSTENUIK, P. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.06.005 · Cited by 281 · see citing works

Regulation of TNF-Induced Osteoclast Differentiation

Yao, Z., Getting, S. J., & Locke, I. C. (2021) · Cells · doi:10.3390/cells11010132 · Cited by 280 · see citing works

Human myeloma cells stimulate the receptor activator of nuclear factor-κB ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease.

Giuliani, N., Colla, S., Sala, R., Moroni, M., Lazzaretti, M., La Monica, S., Bonomini, S., Hojden, M., Sammarelli, G., Barillè, S., et al. (2002) · Blood · doi:10.1182/blood-2002-04-1121 · Cited by 270 · see citing works

The effects of smoking on bone metabolism

Yoon, V., Maalouf, N. M., & Sakhaee, K. (2012) · Osteoporosis International · doi:10.1007/s00198-012-1940-y · Cited by 268 · see citing works

RANK ligand and osteoprotegerin in myeloma bone disease.

Sezer, O., Heider, U., Zavrski, I., Kühne, C. A., & Hofbauer, L. C. (2003) · Blood · doi:10.1182/blood-2002-09-2684 · Cited by 258 · see citing works

Osteoprotegerin Inhibits Vascular Calcification Without Affecting Atherosclerosis in <i> ldlr ^(−/−) </i> Mice

Morony, S., Tintut, Y., Zhang, Z., Cattley, R. C., Van, G., Dwyer, D., Stolina, M., Kostenuik, P. J., & Demer, L. L. (2008) · Circulation · doi:10.1161/circulationaha.107.707380 · Cited by 258 · see citing works

RANKL Expression Is Related to the Differentiation State of Human Osteoblasts

Atkins, G. J., Kostakis, P., Pan, B., Farrugia, A., Gronthos, S., Evdokiou, A., Harrison, K., Findlay, D. M., & Zannettino, A. C. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.6.1088 · Cited by 245 · see citing works

IκB kinase (IKK)β, but not IKKα, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss

Ruocco, M. G., Maeda, S., Park, J. M., Lawrence, T., Hsu, L.-C., Cao, Y., Schett, G., Wagner, E. F., & Karin, M. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20042081 · Cited by 252 · see citing works

Estrogen Regulates Bone Turnover by Targeting RANKL Expression in Bone Lining Cells

Streicher, C., Heyny, A., Andrukhova, O., Haigl, B., Slavic, S., Schüler, C., Kollmann, K., Kantner, I., Sexl, V., Kleiter, M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-06614-0 · Cited by 251 · see citing works

The Progress about the Effect of Osteoprotegerin and its Ligand During Orthodontic Tooth Movement

Tang, L. (2007) · Medical Recapitulate

Inhibition of tooth movement by osteoprotegerin vs. pamidronate under conditions of constant orthodontic force

Keleş, A., Grunes, B., DiFuria, C., Gagari, E., Srinivasan, V., Darendeliler, M. A., Müller, R., Kent, R., & Stashenko, P. (2007) · European Journal Of Oral Sciences · doi:10.1111/j.1600-0722.2007.00433.x · Cited by 61 · see citing works

Osteoprotegerin is present on the membrane of osteoclasts isolated from mouse long bones

Woo, K. M., Choi, Y., Ko, S., Ko, J. S., Oh, K., & Kim, K.-K. (2002) · Experimental & Molecular Medicine · doi:10.1038/emm.2002.49 · Cited by 23 · see citing works

Regulation of osteoclast-mediated bone resorption by microRNA

Ji, L., Li, X., He, S., & Chen, S. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04298-y · Cited by 22 · see citing works

Tocotrienols Regulate Bone Loss through Suppression on Osteoclast Differentiation and Activity: A Systematic Review

Radzi, N. F. M., Ismail, N. A. S., & Alias, E. (2018) · Current Drug Targets · doi:10.2174/1389450119666180207092539 · Cited by 16 · see citing works